共 45 条
- [22] Signal sequence receptor subunit 3: A novel indicator of immunosuppressive tumor microenvironment and clinical benefits from immunotherapyCELLULAR SIGNALLING, 2023, 111Hu, QinWu, GujieMa, HuiyunZhang, JiaxinYang, Zheng
- [23] Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialNature Medicine, 2022, 28 : 1831 - 1839Solange PetersRafal DziadziuszkoAlessandro MorabitoEnriqueta FelipShirish M. GadgeelParneet CheemaManuel CoboZoran AndricCarlos H. BarriosMasafumi YamaguchiEric DansinPongwut DanchaivijitrMelissa JohnsonSilvia NovelloMichael S. MathisenSarah M. ShaganErica SchleifmanJin WangMark YanSimonetta MocciDavid VoongDavid A. FabrizioDavid S. ShamesTodd RiehlDavid R. GandaraTony Mok
- [24] Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialNATURE MEDICINE, 2022, 28 (05) : 939 - +Kim, Edward S.Velcheti, VamsidharMekhail, TarekYun, CindyShagan, Sarah M.Hu, SylviaChaes, Young KwangLeal, Ticiana A.Dowell, Jonathan E.Tsai, Michaela L.Dakhil, Christopher S. R.Stella, PhilipJin, YanlingShames, David S.Schleifman, EricaFabrizio, David A.Phan, SeeSocinski, Mark A.
- [25] A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumabCANCER RESEARCH, 2018, 78 (13)Fabrizio, DavidLieber, DanielMalboeuf, ChristineSilterra, JacobWhite, EmilyCoyne, MichaelBrennan, TinaMa, JieKennedy, MarkSchleifman, EricaPaul, SarahLi, YanShames, DavidCummings, CraigPeters, EricKowanetz, MarcinLipson, DoronOtto, Geoff
- [26] Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialNATURE MEDICINE, 2022, 28 (09) : 1831 - +Peters, SolangeDziadziuszko, RafalMorabito, AlessandroFelip, EnriquetaGadgeel, Shirish M.Cheema, ParneetCobo, ManuelAndric, ZoranBarrios, Carlos H.Yamaguchi, MasafumiDansin, EricDanchaivijitr, PongwutJohnson, MelissaNovello, SilviaMathisen, Michael S.Shagan, Sarah M.Schleifman, EricaWang, JinYan, MarkMocci, SimonettaVoong, DavidFabrizio, David A.Shames, David S.Riehl, ToddGandara, David R.Mok, Tony
- [27] Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialNature Medicine, 2022, 28 : 939 - 945Edward S. KimVamsidhar VelchetiTarek MekhailCindy YunSarah M. ShaganSylvia HuYoung Kwang ChaeTiciana A. LealJonathan E. DowellMichaela L. TsaiChristopher S. R. DakhilPhilip StellaYanling JinDavid S. ShamesErica SchleifmanDavid A. FabrizioSee PhanMark A. Socinski
- [28] Blood first line ready screening trial ( B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastaticANNALS OF ONCOLOGY, 2017, 28Mok, T. S. K.Gadgeel, S.Kim, E. S.Velcheti, V.Hu, S.Riehl, T.Schleifman, E.Paul, S. M.Mocci, S.Shames, D. S.Phan, S.Yun, C.Mathisen, M.Kowanetz, M.Sweere, U.Socinski, M. A.
- [29] Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Chen, BaoQingLiu, Shi-LiangLi, QiaoqiaoLiu, MengzhongYang, HongXi, Mian
- [30] Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST-a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLCCANCER RESEARCH, 2019, 79 (13)Socinski, Mark A.Paul, Sarah M.Yun, CindyHu, SylviaShen, VincentVelcheti, VamsidarMok, Tony S.Gandara, David R.Chae, Young KwangSchleifman, EricaFabrizio, David A.Shames, David S.Phan, SeeKim, Edward S.